Exponent CEO exercises options, sells 3,920 shares

Exponent Inc. President & CEO Catherine Corrigan exercised two non-qualified stock options, acquiring 3,226 and 2,380 shares of common stock at exercise prices of $25.4050 and $29.0500.

Rhea-AI Filing Summary

Exponent Inc. President & CEO Catherine Corrigan exercised two non-qualified stock options, acquiring 3,226 and 2,380 shares of common stock at exercise prices of $25.4050 and $29.0500. She then sold a total of 3,920 shares of common stock, including 2,218 shares at $67.1646 and 1,702 shares at $67.1378, with the stock sale used to cover the option exercise price and taxes as noted in the footnotes.

Insider Trade Summary

Exercise and sale activity reported; no spread calculated

Exercise and Sale 6 txns

Insider Corrigan Catherine

Role President & CEO

Sold 3,920 shs ($263K)

Approx. gross sale proceeds $263K

Approx. exercise cost $151K

Type	Security	Shares	Price	Value
Exercise	Non-Qualified Stock Option (right to buy)	3,226	$0.00	$0.00
Exercise	Non-Qualified Stock Option (right to buy)	2,380	$0.00	$0.00
Exercise	Common Stock	3,226	$25.405	$82K
Sale	Common Stock	2,218	$67.1646	$149K
Exercise	Common Stock	2,380	$29.05	$69K
Sale	Common Stock	1,702	$67.1378	$114K

Holdings After Transaction: Non-Qualified Stock Option (right to buy) — 27,180 contracts (Direct); Common Stock — 94,409 shares (Direct)

Footnotes (3)

1. F1. Stock sale was to cover the option exercise price and taxes.
2. F2. The stock option becomes exercisable in four equal annual installments.
3. F3. Not applicable.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Exponent (EXPO) CEO Catherine Corrigan report on this Form 4?

Catherine Corrigan reported exercising two non-qualified stock options and selling shares of Exponent common stock. She acquired 3,226 and 2,380 shares through option exercises, then sold 3,920 shares, primarily to cover the option exercise price and related taxes, according to the disclosure footnotes.

How many Exponent (EXPO) shares did Catherine Corrigan sell?

Catherine Corrigan sold 3,920 shares of Exponent common stock. The transactions included 2,218 shares sold at $67.1646 per share and 1,702 shares sold at $67.1378 per share, with the filing stating the sales were to cover the option exercise price and taxes.

What stock options did Catherine Corrigan exercise at Exponent (EXPO)?

She exercised two non-qualified stock option awards for Exponent common stock. The exercises covered 3,226 shares at an exercise price of $25.4050 per share and 2,380 shares at $29.0500 per share, converting these derivative securities into Exponent common shares held directly.

Were Catherine Corrigan’s Exponent (EXPO) stock sales open-market transactions?

Yes. The Form 4 classifies both stock sales as open-market or private transactions under code “S.” The disclosed prices of $67.1646 and $67.1378 per share indicate market-based sales conducted after option exercises to fund the exercise cost and associated tax obligations.

Did Catherine Corrigan’s Exponent (EXPO) transactions involve derivative securities?

Yes. The filing shows exercises of non-qualified stock options, which are derivative securities giving a right to buy Exponent common stock. These options were exercised to acquire 3,226 and 2,380 shares, which then became common stock, some of which was sold to cover costs and taxes.

How is Catherine Corrigan’s ownership type described in the Exponent (EXPO) Form 4?

The Form 4 states that Catherine Corrigan’s reported holdings are “direct” ownership. Each transaction is coded with ownership type “direct” and ownership code “D,” indicating the reported Exponent common stock and options are held directly rather than through an intermediary entity or indirect structure.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/18/2026 - 07:43 PM EST Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Corrigan Catherine

(Last) (First) (Middle)

149 COMMONWEALTH DRIVE

(Street)

MENLO PARK CA 94025

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
EXPONENT INC [ EXPO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President & CEO

3. Date of Earliest Transaction (Month/Day/Year)
02/17/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/17/2026		M		3,226	A	$25.405	95,949	D
Common Stock	02/17/2026		S(1)		2,218	D	$67.1646	93,731	D
Common Stock	02/17/2026		M		2,380	A	$29.05	96,111	D
Common Stock	02/17/2026		S(1)		1,702	D	$67.1378	94,409	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Non-Qualified Stock Option (right to buy)	$25.405	02/17/2026		M			3,226	(2)	07/29/2026	Common Stock	3,226	(3)	12,902	D
Non-Qualified Stock Option (right to buy)	$29.05	02/17/2026		M			2,380	(2)	02/16/2027	Common Stock	2,380	(3)	14,278	D

Explanation of Responses:

1. Stock sale was to cover the option exercise price and taxes.

2. The stock option becomes exercisable in four equal annual installments.

3. Not applicable.

	By: Wendy Whitehouse For: Catherine Corrigan	02/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.